Sherry Lewis
Family · Winnsboro, LANPI 1447987177
Payments from drug & device makers
Across 78 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$240
- Lundbeck LLC$177
- Otsuka America Pharmaceutical, Inc.$132
- AbbVie$117
- Novo Nordisk$110
- Merck$95
- plus $570 from 13 others
What the payments were for
- Food & beverage$1,441100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 13 | $240 |
| Lundbeck LLC | 9 | $177 |
| Otsuka America Pharmaceutical, Inc. | 6 | $132 |
| AbbVie | 5 | $117 |
| Novo Nordisk | 7 | $110 |
| Merck | 5 | $95 |
| Exact Sciences | 5 | $86 |
| Esperion Therapeutics, Inc. | 6 | $86 |
| Lilly USA, LLC | 5 | $84 |
| AstraZeneca | 5 | $82 |
| Phathom Pharmaceuticals, Inc. | 2 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Pfizer | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Amgen | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
How this compares
$1,441 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $41,685 |
| MounjaroTirzepatide | 29 | $29,101 |
| RybelsusSemaglutide | 17 | $25,699 |
| ZonegranZonisamide | 11 | $25,059 |
| TrulicityDulaglutide | 22 | $23,547 |
| FarxigaDapagliflozin Propanediol | 15 | $13,604 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,568 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,408 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $1,696 |
| Diclofenac Sodium | 75 | $1,238 |
| Atorvastatin Calcium | 132 | $719 |
| Levocetirizine Dihydrochloride | 74 | $686 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $616 |
| Rosuvastatin Calcium | 60 | $615 |
| Tacrolimus | 11 | $611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $110 | $67,38460 claims |
| Lilly USA, LLCMounjaro, Trulicity | $84 | $52,64851 claims |
| AstraZenecaFarxiga | $82 | $13,60415 claims |
| Boehringer IngelheimStiolto Respimat | $16 | $5,56812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.
Other family in Winnsboro
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.